Sunday, January 29, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Featured News

NIAID-Backed Phase 1b Study to Evaluate Broad-Spectrum Antiviral for Dengue

by Global Biodefense Staff
February 1, 2017
Dengue Virus Broad-Spectrum Treatments

A Phase 1b multiple ascending dose study to evaluate the safety and tolerability of UV-4B has been initiated by Emergency BioSolutions, according to an announcement by the company on Feb 1.

UV-4B is the lead dengue virus therapeutic candidate in Emergent’s iminosugar library. Iminosugars are small molecule therapeutics that target host glycosidase enzymes leading to reduced virus infectivity in multiple viruses such as dengue, Zika, SARS, and influenza.

This novel host-based mechanism of action allows the potential for broad-spectrum application and a reduced probability of developing drug resistance.

Preclinical studies have shown that UV-4B is active in vitro against all four dengue virus subtypes and in vivo studies have shown improved survival even when dosing was delayed by up to 48 hours post-infection.

The new study, which will enroll 40 healthy adults in U.S. sites, follows a successful Phase 1a single ascending dose clinical study completed in 2016.

This study is fully funded under development contract HHSN272201100030C with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health of the U.S. Department of Health and Human Services.

Tags: AntiviralsDengueInfluenzaMosquito-BorneNIAIDSARSZika

Related Posts

DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies
Medical Countermeasures

NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC